bioXcelerate, a new and innovative health data science division of Optima Partners Limited, has revealed a new groundbreaking AI tool, which is set to accelerate the process for identifying and developing new drugs.
RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT Therapeutics’ zelnecirnon is a C-C motif chemokine receptor 4 (CCR4) agonist. Image Credit: Jennie Book / Shutterstock. RAPT Therapeutics has announced plans to terminate